REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This BCC Research report, BIO073A Cancer Profiling and Pathways: Technologies and Global Markets, provides a detailed overview and thorough analysis and insight of the present and future cancer profiling and pathways. This report analyzes in detail the cancer profiling and tools markets. This report includes products in this market, and detailed analyses of markets and competitive environments, cancer markets in newly emerging tools, diagnostics and therapeutics, and their impacts on the market. The report includes information about significant products, key players, issues and trends, current market status of cancer profiling methods, strengths, weaknesses, opportunities and challenges, major issues involved in the research and development (R&D) of more effective cancer profiling techniques, and new cancer therapeutics in development and in clinical trials.
REASONS FOR DOING THE STUDY
Gene expression profiling methods enable the detection and measurement of multiple expressed gene transcripts in a single RNA sample. Continually evolving methods, such as microarray analysis, multiplex PCR, and quantitative real-time PCR, are integral to deciphering the molecular mechanisms involved in gene function, biological development, and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers. Life Technologies, Applied Biosystems division, and Affymetrix, respectively, are maintaining their leads in the quantitative real-time PCR and microarray market segments. Understanding the multivariate nature of cancer and drug response also depends on molecular profiling at epigenetic, genetic, and protein levels. A major challenge is to develop an understanding of this multivariate dysregulation, with respect both to how it arises from diverse genetic mutations and to how it may be ameliorated by prospective treatments. High-throughput experimental platform technologies ranging from genomic sequencing to transcriptomic, proteomic, and metabolomic profiling are now commonly used for molecular-level characterization of tumor cells and surrounding tissues. The global cancer profiling market is projected to be valued at $40.3 billion by 2015, growing at a compound annual growth rate (CAGR) of 20.8% from 2009 to 2015, driven by the high demand for novel and specific biomarkers in the field of drug discovery. The increasing use of biomarkers in clinical services is boosting the overall biomarker service market. The high growth of the biomarker market is boosted by the demand from the baby boomer generation in the U.S., and from Asia’s emerging IT industry.
SCOPE OF REPORT
Cancer biomarkers have gained significant importance in the drug-development process, and the market is an emerging segment. To gain an understanding of the market dynamics, market size, and competitive landscape needs a detailed analysis of cancer biomarker market and cancer profiling technologies and new developments. This report’s exhaustive market segmentation captures relevant data regarding biomarker tools, services, and application markets, and thereby provides a complete picture of the cancer-profiling market. The proposed report will give an update on Cancer Profiling and Pathways: Technologies and Global Markets. It will review global markets for cancer profiling and biomarker studies and will forecast trends for use of technologies through 2015. Important cancer profiling techniques, market share by type of products on the market and market share by company, information for types of cancers and biomarkers will be provided. The report also includes current issues and trends affecting the industry, costs, and factors influencing demand.. The report covers epigenetic, methylation and miRNA products in development, products in clinical trials, currently marketed and clinical-stage development products. The report categorizes the biomarkers and profiling market and provides market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables and also provides company profiles.
The following technologies and segments are excluded from this report: detailed instruments, pharmacogenomics, combinatorial chemistry, biochip, bioinformatics, and high-throughput screening (HTS). Uses of emerging technologies in drug discovery such as lab-on-a-chip (LOAC), nanotechnology, and RNA interference (RNAi) also are not discussed here.
INTENDED AUDIENCE
This report is an exhaustive study on the cancer profiling and pathways, giving crucial statistics and analysis on the market structure, market size, key technologies and segments, important trends in technology development, next-generation technologies, major opportunities, and market shares of key players and innovative drugs. This report may prove crucial for the firms or investors seeking investments in the concerned sector. As market needs change with progress, the value of the information provided from microarrays, sequencing, and qRT-PCR has become more interesting for markets outside of basic life-science research. In oncology-expression pattern profiling, comparing expression in normal and cancer tissues shows an unexpected greater reliability in classifying cancer types than the signatures of protein-coding genes. Researchers have also successfully classified poorly differentiated tumors using expression profiles. Along with their diagnostic potential, cancer-profiling techniques have also reportedly proven to be of prognostic value to predict survival among cancer patients and poor responsiveness to adjuvant chemotherapy and other drugs.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to paid databases. The base year of the report is 2009, with forecast data provided through 2015. Historical, base year, and forecast data are provided for each market segment of this report. Growth rates are determined through a compilation of data, including past trends, future trends, products in R&D, and current product growth, etc.
ANALYST CREDENTIALS
Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has more than 10 years of preclinical, alliance management, discovery, and technology development marketing experience. Her strong focus areas include oncology and cardiovascular diseases, with expertise in molecular and cell biology and complex cell-based biological assays, ranging from drug discovery, in vitro and in vivo screening, in vivo model development, and pharmacokinetics. She has experience working with early start-ups.
BCC ONLINE SERVICES
BCC Research offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
